Nirsevimab and a Community Recall-Based Immunization Strategy for Child Bronchiolitis Prevention - Takeaways - MDSpire

Nirsevimab and a Community Recall-Based Immunization Strategy for Child Bronchiolitis Prevention

  • By

  • Riccardo Boracchini

  • Benedetta Canova

  • Mirko Cesarini

  • Irene De Marchi

  • Giulia Brigadoi

  • Elisa Barbieri

  • Daniele Donà

  • Carlo Giaquinto

  • Eugenio Baraldi

  • Anna Cantarutti

  • May 19, 2026

  • 0 min

Share

  • 1

    Nirsevimab effectively reduces the risk of clinically diagnosed all-cause bronchiolitis in infants, showing 45% to 48% effectiveness.

  • 2

    The study involved a cohort of 4900 infants, comparing immunized and nonimmunized groups in a community pediatric practice.

  • 3

    Infants aged 2 to 3 months benefited most from nirsevimab, with effectiveness decreasing in older age groups.

  • 4

    The recall-based immunization strategy achieved over 80% coverage in the Veneto region, enhancing community health outcomes.

  • 5

    Findings support the implementation of nirsevimab immunization strategies in pediatric practices to prevent bronchiolitis.

Original Source(s)

Nirsevimab and a Community Recall-Based Immunization Strategy for Child Bronchiolitis Prevention

  • by Riccardo Boracchini, Benedetta Canova, Mirko Cesarini, Irene De Marchi, Giulia Brigadoi, Elisa Barbieri, Daniele Donà, Carlo Giaquinto, Eugenio Baraldi, Anna Cantarutti

  • May 19, 2026

Related Content

Age-related Vulnerability and Its Impact on RSV Transmission Patterns and Population Immunization Effects

Assessing PEPFAR’s Health Spillover Effects Beyond HIV: An Update

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.